Viewing Study NCT04156256

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:31 PM
Ignite Modification Date: 2026-01-19 @ 1:24 PM
Study NCT ID: NCT04156256
Status: UNKNOWN
Last Update Posted: 2019-11-12
First Post: 2019-11-06
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
Sponsor: iCell Gene Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hematologic Malignancy View
None Acute Myeloid Leukemia View
None Myelodysplastic Syndromes View
None Myeloproliferative Neoplasm View
None Chronic Myeloid Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None CD123 View
None CD33 View
None CD123-CD33 cCAR View
None Leukemia View
None Hematologic Malignancies View